135 related articles for article (PubMed ID: 32209376)
1. Type 5 17-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3) inhibition and potential anti-proliferative activity of cholest-4-ene-3,6-dione in MCF-7 breast cancer cells.
Sali VK; Mani S; Meenaloshani G; Velmurugan Ilavarasi A; Vasanthi HR
Steroids; 2020 Jul; 159():108638. PubMed ID: 32209376
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
3. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
5. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
6. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.
Penning TM
Expert Opin Ther Pat; 2017 Dec; 27(12):1329-1340. PubMed ID: 28895472
[TBL] [Abstract][Full Text] [Related]
7. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
Byrns MC; Jin Y; Penning TM
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
[TBL] [Abstract][Full Text] [Related]
9. Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
Liu Y; He S; Chen Y; Liu Y; Feng F; Liu W; Guo Q; Zhao L; Sun H
J Med Chem; 2020 Oct; 63(20):11305-11329. PubMed ID: 32463235
[TBL] [Abstract][Full Text] [Related]
10. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Penning TM
Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
[TBL] [Abstract][Full Text] [Related]
11. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
[TBL] [Abstract][Full Text] [Related]
12. Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors.
Zheng X; Jiang Z; Li X; Zhang C; Li Z; Wu Y; Wang X; Zhang C; Luo HB; Xu J; Wu D
Bioorg Med Chem; 2018 Dec; 26(22):5934-5943. PubMed ID: 30429100
[TBL] [Abstract][Full Text] [Related]
13. Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for Breast Cancer Treatment through Computer-Aided Drug Design and In Vitro Analysis.
Fonseca-Benítez V; Acosta-Guzmán P; Sánchez JE; Alarcón Z; Jiménez RA; Guevara-Pulido J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675620
[TBL] [Abstract][Full Text] [Related]
14. Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Endo S; Oguri H; Segawa J; Kawai M; Hu D; Xia S; Okada T; Irie K; Fujii S; Gouda H; Iguchi K; Matsukawa T; Fujimoto N; Nakayama T; Toyooka N; Matsunaga T; Ikari A
J Med Chem; 2020 Sep; 63(18):10396-10411. PubMed ID: 32847363
[TBL] [Abstract][Full Text] [Related]
15. Direct antiproliferative effect of nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors in vitro.
Berényi Á; Frotscher M; Marchais-Oberwinkler S; Hartmann RW; Minorics R; Ocsovszki I; Falkay G; Zupkó I
J Enzyme Inhib Med Chem; 2013 Aug; 28(4):695-703. PubMed ID: 22471733
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
Adeniji A; Uddin MJ; Zang T; Tamae D; Wangtrakuldee P; Marnett LJ; Penning TM
J Med Chem; 2016 Aug; 59(16):7431-44. PubMed ID: 27486833
[TBL] [Abstract][Full Text] [Related]
17. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Verma K; Zang T; Penning TM; Trippier PC
J Med Chem; 2019 Apr; 62(7):3590-3616. PubMed ID: 30836001
[TBL] [Abstract][Full Text] [Related]
18. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
20. New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold.
Pippione AC; Kilic-Kurt Z; Kovachka S; Sainas S; Rolando B; Denasio E; Pors K; Adinolfi S; Zonari D; Bagnati R; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2022 Jul; 237():114366. PubMed ID: 35447434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
